GRAIL, Inc.
GRAL Healthcare Diagnostics & Research
GRAIL, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $147.2 million, up 17.2% from fiscal 2024.
- Revenue
- +3.71%
- EPS
- +10.2%
- Free cash flow
- −24.9%
Quarter to September 2026, against a year earlier
Follow GRAL
Alert me
GRAIL, Inc. (GRAL) P/S ratio
As of 5 November 2026, GRAIL, Inc. (GRAL) trades at a P/S ratio of 34.9×. Over the past ten years it has ranged from 0.0× (June 2024) to 44.6× (October 2026); the current reading is higher than 96% of that period. That is above the Diagnostics & Research industry median of 4.2× and above the Healthcare sector median of 3.5×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 21.4× | 371.44% |
| FY2024 | 4.5× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Sep 2026 | 39.3× | 120.90% |
| Jun 2026 | 17.8× | 32.38% |
| Mar 2026 | 13.5× | (37.06%) |
| Dec 2025 | 21.4× | 41.92% |
| 9 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| ICLR ICON PLC compare | 1.9× |
| RDNT RadNet, Inc. compare | 2.7× |
| VCYT Veracyte, Inc. compare | 3.3× |
| SHC Sotera Health Company compare | 3.7× |
| QGEN QIAGEN N.V. compare | 5.0× |
| CDNA CareDx, Inc. compare | 8.1× |
| BLLN BillionToOne, Inc. compare | 12.1× |
| ADPT Adaptive Biotechnologies Corporation compare | 14.5× |
| GRAL GRAIL, Inc. | 34.9× |
| Diagnostics & Research industry median | 4.2× |
| Healthcare sector median | 3.5× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on GRAL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement